Benitec Biopharma Inc.
Benitec Biopharma Inc. (BNTC) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bntc · pe ratio · data through Jun 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Benitec Biopharma Inc. (BNTC) measures how much investors pay for each dollar of the company's trailing earnings. BNTC's current PE ratio of N/A is calculated by dividing its stock price of $10.60 by its TTM earnings per share of -$0.99.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-06-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Benitec Biopharma Inc.You BNTC | $278M | N/A | — | -$0.99 |
 Autolus Therapeutics plc AUTL | $385M | N/A | — | -$1.08 |
 Galectin Therapeutics Inc. GALT | $156M | N/A | — | -$0.48 |
 I-Mab IMAB | $542M | N/A | — | -$0.27 |
 Lineage Cell Therapeutics, Inc. LCTX | $302M | N/A | — | -$0.28 |
 Neurogene Inc. NGNE | $417M | N/A | — | -$4.27 |
 Ocugen, Inc. OCGN | $433M | N/A | — | -$0.23 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-06-30Latest FY2025 | — | $-1.05 | — | |
2024-06-30 FY2024 | — | $-2.12 | — | |
2023-06-30 FY2023 | — | $-14.12 | — | |
2022-06-30 FY2022 | — | $-9.47 | — | |
2021-06-30 FY2021 | — | $-13.74 | — | |
2020-06-30 FY2020 | — | $-34.43 | — | |
2019-06-30 FY2019 | 21.11x | $9.05 | — | |
2018-06-30 FY2018 | — | $-38.13 | — | |
2017-06-30 FY2017 | — | $-24.33 | — | |
2016-06-30 FY2016 | — | $-123.69 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Benitec Biopharma Inc. (BNTC) measures how much investors pay for each dollar of the company's trailing earnings. BNTC's current PE ratio of N/A is calculated by dividing its stock price of $10.60 by its TTM earnings per share of -$0.99.
Frequently asked questions
BNTC pe ratio · 6 questionsBNTC's current PE ratio is N/A as of 2026-06-08, based on a stock price of $10.60 and TTM EPS of -$0.99. Data sourced from Financial Modeling Prep via BNTC's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Benitec Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08